We are a company focused on the discovery, development, and commercialization of pharmaceutical-grade acid-based (HOCl) therapeutics designed to prevent and treat infection in invasive applications.

Our lead drug candidate, , is a broad spectrum anti-infective that we are developing for the prevention and treatment of infection in surgical and trauma procedures. We are focusing for use initially in due to the large addressable market, high rate of post-surgical infection associated with , the high-impact opportunity that offers us in the clinical trial setting to expose multiple internal organs to RUT58-60 at one time, and feedback from surgeons identifying post-surgical infection in (relative to other surgeries) as a significant unmet medical need.

Tags

 
 
 
 

Enjoy this site? Please spread the word :)

RSS
EMAIL
SHARE